Deleted Tweets From Scott Gottlieb, R-D.C.

RT @SarahKarlin: Livestream link here for @ceboudreau and my convo with @SGottliebFDA at 9:20 am tomorrow (Tuesday) at #PROSUMMIT h… https://t.co/aHj642ip4j

Looking forward to joining @SarahKarlin tomorrow for the Politico Pro Summitt to discuss #FDA policy priorities

RT @DepSecHargan: Great read by former HHS Secretaries Sebelius and Thompson about the need to modernize our Stark and anti-kick back… https://t.co/WZcMA2oDi9

RT @AlecGaffney: *Super* interesting guidance out from the FDA this AM on over-the-counter (OTC) drug labeling. The basics: The FDA… https://t.co/bEp6flw4we

#FDA is working with Hy-Vee to recall Spring Pasta Salad after approximately 20 illnesses in MN, SD, NE and IA were potentially linked to the product. FDA and @CDCgov are investigating the issue and will provide more as it becomes available https://t.co/xbz03TpUxQ https://t.co/UwjoRJCl0d

Today’s drug approval shows benefits of new programs to improve FDA’s review of cancer drugs https://t.co/ajkblxNAYH New pilots to make development & review of cancer drugs more efficient allowed for approval of new use of breast cancer drug less than one month after submission

RT @LorenAdler: Tune in today at 1:30 (or join in person at Brookings) to hear @SGottliebFDA lay out FDA's action plan on biosimila… https://t.co/e9KExnzMgt

RT @US_FDA: It’s summer. Protect yourself from the sun, and check out some info about sunless tanners and bronzers.… https://t.co/rTcAqUeSUL

We expect this new approach to real-time review to become a standard framework for how we more effectively and efficiently evaluate information; allowing better, more thorough reviews of data in less time as we're able to direct how data is analyzed once clinical trial is done

RT @SeemaCMS: There is no better person for this role than @AdamCMMi. Adam brings a wealth of experience & is a natural leader that will de… QT @SecAzar: Excited to have @AdamCMMi taking on the role of Sr. Advisor for Value-Based Transformation and Innovation. Adam's t… https://t.co/QcwUHteIZQ)

The decision for an individual to undergo treatment for opioid use disorder is often a complex and challenging one. #FDA is working to encourage ensure access to, and wider use and understanding of, approved medication-assisted treatments: https://t.co/GbXzEQfiiL #stopMATstigma https://t.co/6msLSPbUXs QT @FDA_Drug_Info: New CDER Conversation – Treatment for Opioid Use Disorder: https://t.co/BYLJslxW0e. https://t.co/JXgS2F4JMB)

Providers routinely update patients’ electronic health records with data on outcomes from medical interventions. This data can be a wealth of info on medical products. #FDA issued a final guidance to help sponsors utilizing EHRs in clinical investigations https://t.co/LMxA88xbqc

#FDA and CDC continue to investigate an outbreak of Salmonella linked to recalled Hy-Vee Spring Pasta Salad https://t.co/xf5Yypur0k CDC reports 21 illnesses in 5 states (IA, MN, MO, NE, SD). Product shouldn’t be available for sale; consumers shouldn’t eat the recalled pasta salad

RT @FDA_Drug_Info: Read the latest "From Our Perspective: Biosimilar Product Labeling": https://t.co/46XnRGn3tq. https://t.co/gRx1157KgN

RT @DrugChannels: For your reading pleasure: Here's the new @US_FDA #biosimilar action plan #BAP announced today by @SGottliebFDA… https://t.co/CeeO7sOAF8

RT @steveusdin1: FDA started reviewing a cancer drug application before it was submitted. Real-time pilot speeds Kisqali label expan… https://t.co/12pyYzQOty

RT @SGottliebFDA: Today’s drug approval shows benefits of new programs to improve FDA’s review of cancer drugs… https://t.co/gbAinVVYhd

RT @BlumenthalG: Nice example of innovative pilots of RTOR (real time oncology review- not to be confused with mTOR) and Assessment Aid to… QT @FDAOncology: FDA expands ribociclib indication in HR-positive, HER2-negative advanced or metastatic #breastcancer. This is FDA's… https://t.co/DmG5xIgzIY)

RT @SeemaCMS: Congrats @US_FDA & @SGottliebFDA on the release of the Biosimilars Action Plan! See my statement on the action plan here: htt… QT @SGottliebFDA: Today #FDA released our #Biosimilars Action Plan outlining how we’ll improve efficiency and scientific and regulato… https://t.co/2jdkM4LEKf)

RT @annaedney: BREAKING: White House is reviewing a proposal to curb rebates drugmakers offer PBMs and insurers that are blamed fo… https://t.co/szCJa7uNcl

RT @SarahKarlin: Livestream link here for @ceboudreau and my convo with @SGottliebFDA at 9:20 am tomorrow (Tuesday) at #PROSUMMIT h… https://t.co/aHj642ip4j

Looking forward to joining @SarahKarlin tomorrow for the Politico Pro Summitt to discuss #FDA policy priorities

RT @DepSecHargan: Great read by former HHS Secretaries Sebelius and Thompson about the need to modernize our Stark and anti-kick back… https://t.co/WZcMA2oDi9

RT @AlecGaffney: *Super* interesting guidance out from the FDA this AM on over-the-counter (OTC) drug labeling. The basics: The FDA… https://t.co/bEp6flw4we

#FDA is working with Hy-Vee to recall Spring Pasta Salad after approximately 20 illnesses in MN, SD, NE and IA were potentially linked to the product. FDA and @CDCgov are investigating the issue and will provide more as it becomes available https://t.co/xbz03TpUxQ https://t.co/UwjoRJCl0d

Today’s drug approval shows benefits of new programs to improve FDA’s review of cancer drugs https://t.co/ajkblxNAYH New pilots to make development & review of cancer drugs more efficient allowed for approval of new use of breast cancer drug less than one month after submission

RT @LorenAdler: Tune in today at 1:30 (or join in person at Brookings) to hear @SGottliebFDA lay out FDA's action plan on biosimila… https://t.co/e9KExnzMgt

RT @US_FDA: It’s summer. Protect yourself from the sun, and check out some info about sunless tanners and bronzers.… https://t.co/rTcAqUeSUL

We expect this new approach to real-time review to become a standard framework for how we more effectively and efficiently evaluate information; allowing better, more thorough reviews of data in less time as we're able to direct how data is analyzed once clinical trial is done

RT @SeemaCMS: There is no better person for this role than @AdamCMMi. Adam brings a wealth of experience & is a natural leader that will de… QT @SecAzar: Excited to have @AdamCMMi taking on the role of Sr. Advisor for Value-Based Transformation and Innovation. Adam's t… https://t.co/QcwUHteIZQ)

The decision for an individual to undergo treatment for opioid use disorder is often a complex and challenging one. #FDA is working to encourage ensure access to, and wider use and understanding of, approved medication-assisted treatments: https://t.co/GbXzEQfiiL #stopMATstigma https://t.co/6msLSPbUXs QT @FDA_Drug_Info: New CDER Conversation – Treatment for Opioid Use Disorder: https://t.co/BYLJslxW0e. https://t.co/JXgS2F4JMB)

Providers routinely update patients’ electronic health records with data on outcomes from medical interventions. This data can be a wealth of info on medical products. #FDA issued a final guidance to help sponsors utilizing EHRs in clinical investigations https://t.co/LMxA88xbqc

#FDA and CDC continue to investigate an outbreak of Salmonella linked to recalled Hy-Vee Spring Pasta Salad https://t.co/xf5Yypur0k CDC reports 21 illnesses in 5 states (IA, MN, MO, NE, SD). Product shouldn’t be available for sale; consumers shouldn’t eat the recalled pasta salad

RT @FDA_Drug_Info: Read the latest "From Our Perspective: Biosimilar Product Labeling": https://t.co/46XnRGn3tq. https://t.co/gRx1157KgN

RT @DrugChannels: For your reading pleasure: Here's the new @US_FDA #biosimilar action plan #BAP announced today by @SGottliebFDA… https://t.co/CeeO7sOAF8

RT @steveusdin1: FDA started reviewing a cancer drug application before it was submitted. Real-time pilot speeds Kisqali label expan… https://t.co/12pyYzQOty

RT @SGottliebFDA: Today’s drug approval shows benefits of new programs to improve FDA’s review of cancer drugs… https://t.co/gbAinVVYhd

RT @BlumenthalG: Nice example of innovative pilots of RTOR (real time oncology review- not to be confused with mTOR) and Assessment Aid to… QT @FDAOncology: FDA expands ribociclib indication in HR-positive, HER2-negative advanced or metastatic #breastcancer. This is FDA's… https://t.co/DmG5xIgzIY)

RT @SeemaCMS: Congrats @US_FDA & @SGottliebFDA on the release of the Biosimilars Action Plan! See my statement on the action plan here: htt… QT @SGottliebFDA: Today #FDA released our #Biosimilars Action Plan outlining how we’ll improve efficiency and scientific and regulato… https://t.co/2jdkM4LEKf)

RT @annaedney: BREAKING: White House is reviewing a proposal to curb rebates drugmakers offer PBMs and insurers that are blamed fo… https://t.co/szCJa7uNcl